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Introduction:  Cervical  cancer  screening  and  existing  health  insurance  schemes  in  China  fall  short  of  reach-
ing  women  with  prevention  and  treatment  services,  especially  in rural  areas  where  the  disease  burden
is  greatest.  We  conducted  an  extended  cost-effectiveness  analysis  (ECEA)  to evaluate  public ﬁnancing  of
HPV vaccination  to prevent  cervical  cancer,  adding  new  dimensions  to  conventional  cost-effectiveness
analysis through  an  explicit  inclusion  of equity  and  impact  on  ﬁnancial  risk  protection.
Methods: We  synthesized  available  epidemiological,  clinical,  and  economic  data  from  China  using an
individual-based  Monte  Carlo  simulation  model  of  cervical  cancer  to estimate  the distribution  of  deaths
averted  by income  quintile,  comparing  vaccination  plus  screening  against  current  practice.  We  also  esti-
mated  reductions  in cervical  cancer  incidence,  net  costs  to  the  government  (HPV  vaccination  costs  minus
cervical  cancer  treatment  costs  averted),  and  patient  cost  savings,  as  well  as the incremental  government
health care  costs  per  death  averted.
Results:  HPV  vaccination  is cost-effective  across  all income  groups  when  the  cost  is  less  than  US  $50
per  vaccinated  girl. Compared  to  screening  alone,  adding  preadolescent  HPV  vaccination  followed  by
cervical  cancer  screening  in  adulthood  could  reduce  cancer  by 44  percent  across  all  income  groups,  while
providing  relatively  higher  ﬁnancial  protection  to the  poorest  women.  The  absolute  numbers  of cervical
cancer  deaths  averted  and  the  ﬁnancial  risk  protection  from  HPV  vaccination  are  highest  among  women
in  the lowest  quintile;  women  in  the bottom  income  quintiles  received  higher  beneﬁts  than  those  in the
upper  wealth  quintiles.  Patient  cost savings  represent  a large  proportion  of  poor  women’s  average  per
capita  income,  reaching  60 percent  among  women  in  the bottom  income  quintile  and declining  to  15
percent  among  women  in  the  wealthiest  quintile.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Cervical cancer is one of the most common diseases affecting
omen in China. While average national estimates are low, cervical
ancer burden may  be underestimated, as human papillomavirus
HPV) prevalence is high. Cervical cancer mortality is heteroge-
eous across geographic settings; and highest among poor women
n Gansu, Shanxi, and Shaanxi, the least developed provinces in
entral and western China.
∗ Corresponding author. Tel.: +1 206 744 3790; fax: +1 206 744 3694.
E-mail address: clevin@uw.edu (C.E. Levin).
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.052
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
The low national cervical cancer estimates may  be the result of
the lack of a nationwide cancer registry. Most registries are located
in urban areas, where the socioeconomic status of women is higher
and cancer disease burden is likely lower than rural areas [1]. While
HPV prevalence has been found to be similar in rural and urban
regions, cervical cancer mortality is signiﬁcantly higher in rural
areas. This disproportionate burden is likely attributable to unequal
availability and utilization of health services including screening
and treatment.
In the absence of a national cervical cancer-screening program
in China, screening is opportunistic. From 2009 to 2011, the
Chinese government initiated a program to provide free cervical
cancer screening for 10 million rural women between 35 and 59
years of age which covered only 7% of women due to shortages
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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f gynecologists and cytologists and an overburdened health care
ystem [2,3]. With an estimated 700 million women  in China,
caling up preventative services is formidable [4–7].
China’s health care system has been evolving to respond to
he pervasive unequal access to health services. In 2009, China
egan to introduce universal health coverage [8], reaching high
overage in urban and rural areas with two government-sponsored
chemes. Despite high coverage, reimbursement is limited to inpa-
ient expenses. It is unclear how recent health insurance schemes
ave impacted women’s cervical cancer treatment rates; however,
ecent studies indicate that services are not reaching poorer women
1,5,9]. This trend is likely to continue until insurance schemes
over outpatient services.
While widespread screening with cytology has dramatically
educed the cervical cancer burden in developed countries, low-
esource settings lack the infrastructure and resources to achieve
imilar cancer reductions. Newer screening technologies that are
heaper, cost-effective and easier to implement than cytology can
educe the cervical cancer burden among Chinese women, pro-
ecting them from future costs and consequences of the disease
4,10–13].
HPV vaccination is a promising primary prevention strategy
gainst cervical cancer. Studies indicate that screening women
nd vaccinating preadolescent girls against HPV is cost-effective
n reducing the burden of cervical cancer in China [10,11,14,15].
accination strategies were cost-effective up to US$55 per vac-
inated girl, with incremental cost-effectiveness ratios (ICER) of
S$2746 per life year saved (LYS) when vaccination was combined
ith screening once in a lifetime, and up to US$5963 per LYS when
ombined with screening ﬁve times in a lifetime [14]. At, US$25 per
accinated girl the ICER declines to US$1360 per LYS.
Recent attention to reaching the goal of universal health cov-
rage (UHC) provides strong rationale for exploring mechanisms
o expand access to cervical cancer prevention and treatment in
hina without increasing ﬁnancial burden of women  seeking care
16]. We  sought to apply an extended cost-effectiveness analysis
ECEA) methodology [17,18,49] to evaluate public ﬁnancing of HPV
accination for cervical cancer prevention. Recent theoretical and
mpirical work provides guidance in this area; either focused on
pplications for high-income countries or limited to a few infec-
ious disease conditions in a number of low- and middle-income
ountries [19–21]. In this application, ECEA adds new dimen-
ions to conventional cost-effectiveness analysis (CEA) through a
ore explicit treatment of equity and impact on ﬁnancial risk
rotection (prevention of medical impoverishment) [17]. Speciﬁ-
ally, ECEA can evaluate publicly ﬁnanced programs by measuring
rogram impact along four main dimensions: (i) health beneﬁts;
ii) household private expenditures averted (“household cost sav-
ngs”); (iii) ﬁnancial risk protection provided to households; and
iv) distributional consequences across the wealth strata of coun-
ry populations. As a result, ECEA enables quantitative inclusion
f information on equity and amount of ﬁnancial risk protection
ought per dollar expenditure on health policy, in addition to
mount of health bought [17].
Consequently, the distribution of health and ﬁnancial beneﬁts
esulting from interventions—and by extension from the policy
nstruments that ﬁnance them—can be examined to determine
hether they are pro-poor. In practice, ECEAs can also be used to
xamine ﬁnancial effects of interventions and policies on individ-
als or families by income group and in aggregate. Health policies
nd interventions typically involve costs to the public sector and
ouseholds. Even if an intervention is provided at no cost, users
ften incur time costs to travel or wait at a health facility; value
laced on these costs differs according to income level.
Publicly ﬁnanced health interventions can help users to avoid
uture costs; for example, HPV vaccination and cancer screening (2015) 2830–2841 2831
programs reduce the cervical cancer risk, which might otherwise
lead to medical impoverishment (related to expensive medical bills
for cancer treatments), devastating health consequences (e.g. death
of a mother, which increases the mortality risk for children), or
both.
We evaluated the consequences of full public ﬁnance of HPV vac-
cination in China using ECEA methodology. Public ﬁnance increases
HPV vaccination uptake, leading to important health gains and can
reduce household medical expenditures. Finally, public ﬁnance can
have differential impacts among populations of different income
levels. We  estimated the level and distribution (across income
groups) of the cervical cancer deaths averted; the households’
expenditures related to cervical cancer treatment averted and the
costs needed to sustain the HPV program; and ﬁnancial risk pro-
tection, using a combination of indicators, detailed below.
2. Methods
2.1. Model
We synthesized available epidemiological, clinical, and eco-
nomic data from China using a previously described individual-
based Monte Carlo simulation model of cervical cancer [23–26].
The model consists of health states representing important clinical
stages of disease, including HPV infection, grade of precancerous
lesions, and stage of invasive cancer. We  evaluate vaccination and
screening as a combined strategy in a single cohort, such that pre-
adolescent girls who are vaccinated will eventually also receive
screening. Thus, individual girls enter the model at age nine, before
sexual debut and free of HPV infection, and they transition between
health states throughout their lifetime. Each month, women face a
risk of acquiring HPV infection; once infected, they can clear their
infection or develop low- or high-grade lesions, categorized as cer-
vical intraepithelial neoplasia, grade 1 (CIN 1) or grade 2,3 (CIN 2,3).
Low-grade lesions can regress, and CIN 2,3 can progress to invasive
cancer. These transitions are determined by age, HPV type, and
type-speciﬁc natural immunity after clearance of HPV infections.
See appendix Fig. A1 for model schematic cervical cancer can be
detected through symptoms or screening, and women with cancer
survive according to stage-speciﬁc survival rates for local, regional,
and metastatic disease.
All women are subject to mortality from competing causes [27].
Our approach was  to calibrate the model for cervical cancer bur-
den of the country as a whole. Model parameters were initially
established using the best available information on the natural his-
tory of HPV infection and cervical carcinogenesis. The model was
adapted to the context in China using likelihood-based methods
to ﬁt the parameters to epidemiological data. Age-speciﬁc cervi-
cal cancer estimates were obtained from GLOBOCAN [28]; data on
HPV 16 and 18-type distribution in CIN 23 and cervical cancer were
from a meta-analysis of primary data from Asia [29]. Baseline natu-
ral history parameters were allowed to vary over plausible ranges.
We identiﬁed sets of parameter values that achieved close ﬁt to the
empirical data and conducted the analysis using the parameter set
with the maximum likelihood.
2.2. Strategies and assumptions
We simulated screening with cytology and visual inspection
with acetic acid (VIA) beginning at age 35 at ﬁve-year intervals
for a cohort of one million women in each income quintile. We
assumed screening frequency progressively increased with income,
with women in the lowest two quintiles screened once per lifetime
at 21 and 34 percent coverage respectively, those in the next two
quintiles screened three times per lifetime at 43 and 47 percent
2 cine 33 (2015) 2830–2841
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Table 1
Summary of the parameters used for modeling the impact and costs of a publicly
ﬁnanced HPV vaccination policy in China.
Parameter Estimate Sources
Screening with cytology: frequency1 and coverage (percent)
Income quintile (lowest to highest)
1. Once per lifetime 21 a,b
2. Once per lifetime 34 a,b
3. Three times per lifetime 43 a,b
4. Three times per lifetime 47 a,b
5. Five times per lifetime 51 a,b
Loss to follow up (percent)
Income quintile (lowest to highest)
1 62 Assumed
2 40 Assumed
3 22 Assumed
4 13 Assumed
5 5 Assumed
Vaccine characteristics
Vaccination coverage (percent) 70 Assumed
HPV2 vaccine price per dose (US$) 13 Assumed
Incremental vaccine program delivery
cost per fully immunized girl (US$)
5 Assumed
Vaccine cost per fully immunized girl,
including wastage and handling
(US$)
46 Assumed
Income and wages
Gross domestic product per capita
(2009 US$)
3749 c
Mean GDP per capita
Income quintile (lowest to highest)
1 783 b, c
2  1633 b,c
3 2567 b,c
4 3888 b,c
5 7896 b,c
Mean wage rate
Income quintile (lowest to highest)
1 $3 c,d
2 $6 c,d
3 $10 c,d
4 $15 c,d
5 $30 c,d
Sources:
a. Gakidou, Nordhagen, and Obermeyer (2008) [36].
b. World Health Organization (2012) [16].
c.  World Health Organization Global Health Observatory [37].
d.  Shi and others (2012) [38].
Note:832 C.E. Levin et al. / Vac
overage, and those in highest screened ﬁve times per lifetime at
1 percent coverage. Consistent with assumptions from previous
nalyses [30,31], cytology was assumed to occur in three visits, ini-
ial screening (visit 1), colposcopy and biopsy for screen-positives
visit 2), and treatment of precancerous lesions or invasive can-
er (visit 3) with loop electrosurgical excision procedure (LEEP),
old knife conization, simple hysterectomy, or simple radiotherapy,
epending on lesion size or cancer stage. VIA screening incorpo-
ates same-day screening and treatment for screen positives [32].
Cancer treatment was assumed to be a mixture of different
pproaches (i.e., cold knife conization, simple hysterectomy, radical
ysterectomy, simple radiotherapy, neoadjuvant chemotherapy,
nd adjuvant chemotherapy), and the distribution of women
eceiving one treatment versus another varied on urban/rural set-
ing and quintile as a way to capture differential access to cancer
reatments. In particular, stage I cancer was assumed to be treated
ith 90% cold knife and 10% simple hysterectomy for quintiles
, 2, and 3, and 30% cold knife and 70% simple hysterectomy for
uintiles 4 and 5. Stage II cancer was assumed to be treated with
0% simple hysterectomy and 10% radical hysterectomy for quin-
iles 1, 2, and 3 in urban areas and 100% simple hysterectomy in
ural areas and 70% simple and 30% radical hysterectomy for quin-
iles 4 and 5 in both urban and rural areas. Stage III and IV cancer
ere assumed to be treated with 80% simple radiotherapy and
0% adjuvant chemotherapy in quintiles 1,2, and 3, and 70% sim-
le radiotherapy, 20% adjuvant chemotherapy and 10 neoadjuvant
hemotherapy in quintiles 4 and 5.
Vaccination was assumed to occur before age 12 (prior to
exual debut) with full three-dose adherence and complete and
ifelong protection against HPV 16 and 18 infections (with no cross-
rotection for non 16/18 types). HPV vaccination coverage was
ssumed at 70 percent coverage based on current immunization
ates of over 95% for childhood vaccines and recent evidence on
he feasibility of reaching pre-adolescent girls with HPV vaccina-
ion using facility, school-based and outreach strategies [33,34]. We
sed screening coverage estimates by quintile from the WHO  Study
n Global AGEing and adult health [16]. Because of lack of data on
oss to follow-up from treatment by quintile in China, we used vari-
tion in treatment seeking rates for non-communicable diseases for
atients across the 5 income groups obtained from the WHO  Study
n global AGEing and adult health (SAGE). We  created weights
ased on this variation adjusted them so the weighted average
f loss-to follow-up would be close to 15% per healthcare visit,
he percentage traditionally used in the literature [24,35]. Our loss
o follow up estimates ranged from 62 percent to 5 percent from
owest to highest quintile, respectively. Recognizing that service
tilization and loss to follow up will be inﬂuenced by heterogeneity
n health system, spatial and socio-economic factors across China’s
rovinces, we conducted a sensitivity analysis on screening cover-
ge and loss to follow-up by quintile. Table 1 summarizes model
arameters.
We estimated the reduction in cervical cancer, distribution of
eaths averted by income quintile, comparing vaccination plus
creening against screening at current coverage. Incremental gov-
rnment costs were equal to HPV vaccination costs minus cervical
ancer treatment costs averted and patient cost savings. Financial
isks can occur when out-of-pocket household expenditures are
ubstantial and can be considered ‘catastrophic’, increasing the
isk of medical impoverishment. While the deﬁnitions and thresh-
lds of catastrophic expenditures vary widely in the literature
nd in practice ([39–41]), typical measures deﬁne catastrophic
pending using a threshold for OOP expenditures’ share of total
ousehold expenditures, ranging from 10% to 40% depending on
he setting. Here, we include two simple indicators of ﬁnancial
isk protection using a combination of indicators to measure the
rotection against ﬁnancial risk from catastrophic expenses or1. We estimated the frequency of screening at 1× and 5× per lifetime for all income
quintiles in sensitivity analysis.
2. HPV = human papillomavirus.
medical impoverishment, including the number of women  who
would avoid cervical cancer treatment out-of-pocket expenditures,
and the average out-of-pocket expenditures averted as a share of
average per capita income, measured by gross domestic product
(GDP). All results are presented by income quintile.
2.3. Costs
Direct medical and non-medical costs were estimated using
published cost from two studies in China ([10,27]) expressed in
2009 US$. We  assumed an average health-seeking behavior by
income quintile and geographic location, where in the lowest three
income quintiles rural and urban women were screened at the
township (primary health center) and county hospital, respectively,
and all women in these lower quintiles received diagnosis and
treatment at the county hospital. We  assumed that in the highest
two income quintiles, rural and urban women were screened and
treated at prefecture and provincial level hospitals respectively.
cine 33
d
p
c
t
t
m
r
t
t
a
a
U
a
B
t
C
g
(
(
p
U
d
(
a
i
l
p
c
2
d
U
c
c
T
y
3
c
r
c
n
p
l
r
t
a
T
BC.E. Levin et al. / Vac
We  then applied a weighted average unit cost for screening,
iagnosis, and treatment based on urban and rural population pro-
ortions by quintile. To estimate household and government costs
onsequences, we assumed 35 percent of cancer screening and
reatment costs remain privately ﬁnanced in China [37]. Patient
ime costs for transportation and waiting were based on time esti-
ates from Shi et al. [27], using an updated national average wage
ate in China ranging from US$3 to US$30 per day for the lowest
o highest quintile, respectively. The average wage rate is equal
o average per capita income divided by 255 workdays per year
t 8 h per day [27]. We  obtained the GDP from the World Bank
nd used the Consumer Price Index (CPI) to deﬂate costs to 2009
S$. Per capita income for each quintile is the proportion of GDP
ccrued to each income quintile using estimates from the World
ank and PovCalNet, an online poverty analysis tool, divided by the
otal population per quintile [42].
Commercially available HPV vaccines are not yet approved in
hina, but vaccines are offered at low prices for public sector pro-
rams from the Global Alliance for Vaccines and Immunization
GAVI) at US$5 and from the Pan American Health Organization
PAHO) countries at US$13 [43]. China could likely negotiate lower
ublic sector prices [2], and we assumed a public sector cost of
S$46 per fully immunized girl, including the vaccine price (three
oses at US$13 per dose), vaccine wastage (2 percent), freight
6 percent), and program administration costs (US$5). Program
dministration costs are lower than the average incremental costs
n recent studies in Sub-Saharan Africa and Latin America, but are
ikely to reﬂect economies of scale that are found in more densely
opulated Asian countries [44]. Annex Tables A2 and A3 summarize
ost estimates by quintile.
.4. Sensitivity analyses
To accommodate the uncertainty around uptake and vaccine
elivery costs, we varied the cost per fully immunized girl from
S$10 and US$100. We  also varied screening frequency, screening
overage and loss to follow up rates. We  uniformly increased can-
er treatment costs by 50 and 100 percent for all quintiles. Annex
able A4 provides the estimates or ranges used in sensitivity anal-
sis.
. Results
We  found that adding preadolescent HPV vaccination at 70 per-
ent coverage to current screening will yield a 44 percent cancer
eduction across all income quintiles (Table 2). While the relative
ancer reduction is constant across income groups, the absolute
umber of cervical cancer deaths averted and the ﬁnancial risk
rotection from HPV vaccination are highest among women in the
owest quintile; women in the bottom income quintiles received
elatively higher cost beneﬁts compared to the upper wealth quin-
iles. HPV vaccination averts 15 percent more detected cancer cases
nd 18 percent more deaths in the lowest compared to the high-
able 2
eneﬁts and costs of a publicly ﬁnanced HPV vaccination policy in China (2009 US$).
Quintile I 
Deaths averted per million women 2877 
Government costs per million women
(incremental)
$31,417,285 $31,42
Government cost per death averted $10,920 $1
Treatment seeking cases of cancer averted
per million women
3540 
Patient cost savings per million women $1,633,160 $2,24
Savings as a percentage of total income 59 
Cancer reduction (percent) 44  (2015) 2830–2841 2833
est quintile. Although in absolute dollars, patient savings were
higher in the top income quintile compared to the lowest quintile
(US$7,655,200 compared to US$1,636,270), the cost savings from
HPV vaccination comprised a larger share of per capita income
among women  in the bottom income quintiles, ranging from 60
percent among the lowest income quintile to 30 percent among
the highest quintile.
At a vaccine cost of US$46 per fully immunized girl and 70%
coverage, the incremental cost is approximately US$160 million for
a cohort of ﬁve million girls. At the relatively low levels of cancer
screening and treatment in China, government intervention costs
do not vary by wealth strata, since medical savings are offset by the
publically ﬁnanced HPV vaccination costs.
Given China’s low reported rates of cervical cancer screening,
our results were robust to changes in assumptions about screening
frequency, screening coverage, and loss to follow-up (Annex
Table A4). As expected, changes in the cost per fully immunized
girl do not have an impact on deaths averted, cancer reduction
or ﬁnancial risk protection, assuming that 70 percent coverage is
maintained. At US$10 per fully vaccinated girl, the cost per death
averted declines to US$2161 for the lowest income quintile to
US$2608 among the highest quintile. At US$100 per vaccinated girl,
cost per death averted increases to US$24,000 in the lowest income
quintile to over US$29,000 in the highest income quintile (Annex
Table A5). Universal coverage of the HPV vaccination becomes even
more favorable among individuals in lower income quintiles and
provides greater relative ﬁnancial risk protection when treatment
costs increased by an additional 50 or 100 percent (Annex Table A6).
4. Discussion
While the HPV vaccine holds great promise for reducing the bur-
den of cervical cancer, it is not yet available in China. Delaying HPV
vaccine introduction will result in a lost opportunity to prevent
cervical cancer cases and deaths. A national vaccination program
of 9–15 year old girls, between 2006 and 2012 could have pre-
vented 381,000 cervical cancer cases and 212,000 related deaths in
the coming decades [2]. While it is expected that China could nego-
tiate HPV vaccine prices to cost effective levels of around US $9 to
13 per dose, at least one-third of Chinese women are not willing to
pay more than US$3 [45]. A successful program will likely depend
on government ﬁnancing.
We applied an ECEA to evaluate the impact of a publically
ﬁnanced policy for HPV vaccination in China on the distribution
of health consequences and ﬁnancial risk protection across income
levels. Results show that preadolescent HPV vaccination added to
current practice could reduce cancer by over 40 percent across
income groups, while providing relatively higher ﬁnancial pro-
tection to households in the bottom income quintiles. The low
screening coverage rates reported for China affect both the gov-
ernment and patient screening and treatment costs, but with
differential results. From the governmental perspective, a publi-
cally ﬁnanced HPV vaccination program would increase net costs,
II III IV V
2854 2667 2604 2362
0,191 $31,440,420 $31,446,679 $31,359,970
1,009 $11,789 $12,076 $13,277
3511 3312 3256 2999
0,688 $2,785,626 $4,417,303 $7,041,335
39 33 35 30
44 43 43 44
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The model outputs using each input parameter set were com-
pared to the calibration targets. Model ﬁt to the targets was
evaluated by constructing a goodness-of-ﬁt score. A composite
goodness-of-ﬁt score for each parameter set was  computed by
summing the log likelihood of each model outcome [25]. Goodness-
of-ﬁt scores followed a chi square distribution with the number of
degrees of freedom equal to the number of targets.
Input parameter acceptance criterion834 C.E. Levin et al. / Vac
ith little offset from averted cervical-related treatment costs due
o the low levels of screening. Although HPV vaccination led to
atient cost savings that were small relative to the increase in
overnment costs, all income groups experienced cost savings;
mportantly, there was a powerful equity effect, with higher ﬁnan-
ial risk protection in the poorest groups. Patient cost savings
epresent a large proportion of poor women’s average per capita
ncome, reaching 60 percent among women in the bottom income
uintile and declining to 15 percent among women living in the
ealthiest quintile. We  also estimated standard cost-effectiveness
atios (results available from the authors) and found that like pre-
ious studies conducted in China, HPV vaccination is cost-effective
cross all income groups when the cost is less than US $50 per
accinated girl.
We assumed a cost of US$46 per vaccinated girl, using US$13
er dose, based on the manufacturers’ offer price to PAHO for pub-
ic vaccination programs in Latin America and the Caribbean. The
nancial cost of vaccinating 70 percent of China’s current cohort of
.6 million 10-year-old girls is US$213 million. This estimate, which
ccounts for less than 1/2 percent of projected health care spend-
ng of US$357 billion in 2011, would have a large ﬁnancial impact
n China’s current Expanded Program for Immunization (EPI). The
ntroduction of the HPV vaccine would require a change in policy to
ublically ﬁnance the HPV vaccine, either through current health
nsurance schemes or through inclusion in the EPI, which provides
ree childhood vaccines for measles, diphtheria/tetanus/pertussis
DTP), Bacille Calmette Guerin (BCG), polio, and hepatitis B. The EPI
anages non-EPI vaccines, such as those for Japanese encephali-
is, mumps, and rubella, but patients pay for these vaccines via
ser fees. A third type of “optional” vaccines, such as hepatitis A,
aemophilus inﬂuenza type B (Hib), and rotavirus, are procured
nd delivered outside of the EPI and paid for by patients without
ny government subsidy [46].
This analysis has a number of limitations: First, it is an appli-
ation of the ECEA method using the best available published
ata from selected provinces, which does not fully capture the
eterogeneity in disease burden, health systems, socio-economic
evelopment and GDP per capita across China’s provinces. Sec-
nd, the ECEA simulates the costs and impacts of HPV vaccination
y income quintile; however, there are limited data on the varia-
ion of HPV incidence, mortality rates, loss to follow-up rates for
creening, and out-of-pocket health expenses by income category.
hird, there is limited information on health service utilization,
creening and treatment costs and the impact of mandatory health
nsurance by prefecture, province and other geographic settings
r across wealth strata. Fourth, we estimated women’s time using
 wage rate derived from a national estimate of per capita GDP
ncome, which may  overestimate income in the lowest quintile,
here some rural communities are likely to live on $US2.00 per
ay or less. In addition, we did not include women’s transport
osts in seeking screening, treatment, or vaccination; these costs
re expected to be small components of patient costs based on
revious analyses in China. Further, estimates of women’s wages
o not include work in the informal sector and therefore may  be
nderestimates of true opportunity costs [10,14,27]. Additionally,
e do not have information of sexual behavior and HPV prevalence
y income quintile. In the absence of such data, we assumed that
ge-speciﬁc HPV prevalence did not vary by quintile, but rather
creening coverage and uptake was the main driver of differences
n cervical cancer incidence.
An ECEA approach yields new and essential information on a
olicy’s ability to reduce inequity and catastrophic expenses that
omplements information on value for money from traditional
ost-effectiveness analyses. Future applications of this approach
ill beneﬁt from improved information on public and private
ealth ﬁnancing, as well as from disaggregated data on disease (2015) 2830–2841
burden and health service utilization by key socio-economic, demo-
graphic, and geographic variables.
A recent editorial recognizing China’s cervical cancer burden
and its unequal impact among disadvantaged women  proposes
a semi-mandatory HPV vaccination program in China targeted to
low-income, high-risk women living in regions with historically
high cervical cancer incidence [47]. Our analysis provides decision
makers with the potential distributional consequence and ﬁnan-
cial risk protection of including cervical cancer in future health care
reform investments to provide insight to policy debates in China. An
ECEA provides additional evidence beyond effectiveness, costs and
cost-effectiveness for selective resource allocation to the popula-
tions and provinces most in need in the context of public ﬁnancing
and the strengthening of Chinese health reform.
Previous research has demonstrated that HPV vaccination in
China can be cost-effective at a cost of US$50 per vaccinated girl,
and a targeted program may  even be affordable given China’s plans
for dramatically increasing health care spending in the near future
[44,47]. Ensuring high and uniform HPV vaccine uptake is likely to
also contribute to more equitable gains with respect to the reduc-
tion of morbidity and mortality from cervical cancer, and it has the
potential to protect women in poor households against catastrophic
cervical cancer medical expenses.
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Annex.
Fig. A1.
Tables A1–A6.
Figs. A2 and A3.
Deﬁning calibration targets
Calibration targets included type distribution within CIN cate-
gories, age-speciﬁc cancer incidence, cumulative cancer incidence,
and type- and age-speciﬁc duration of HPV infections and CIN.
For each calibration target, we  determined a point estimate and
conﬁdence interval, using the best available data sources. Targets
were calculated using 95% conﬁdence intervals of the binomial dis-
tribution in STATA/SE 9.0.
Goodness-of-ﬁtWe determined our best-ﬁtting parameter set as the one with
the lowest goodness-of-ﬁt score – the model-generated input
parameter whose simulated model outputs were simultaneously
closest to all calibration targets.
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Fig. A1. Model natural history of cervical cancer pathogenesis.
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Fig. A2. Calibration results: cervical cancer incidence from best-ﬁtting parameter set, compared with empirical estimates. Black lines depict the 95 percent conﬁdence
intervals of age-speciﬁc cervical cancer incidence in China [28]. Red dashed line represents the projected incidence of the best-ﬁtting parameter set used in model analysis.
(For  interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version of the article.)
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interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version of the article.)
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Table A1
Input parameters: baseline ranges.a
Variable Baseline valuesb Rangesb
Progression
Normal to HPV DNA
- Low-risk (LR) HPV 0.000100–0.010000 0.1–8
-  High-risk other (HR-other) HPV 0.000100–0.010000 0.1–8
-  High-risk (HR-16) HPV 0.000100–0.010000 0.1–8
-  High-risk 18 (HR-18) HPV 0.000100–0.010000 0.1–6
HPV DNA to CIN 1c
- LR HPV 0.004640–0.005380 0.1–6
-  HR-other HPV 0.004780–0.008490 0.1–6
- HR-16 HPV 0.004780–0.008490 0.1–6
-  HR-18 HPV 0.004780–0.008490 0.1–6
HPV DNA to CIN 2,3d
- LR HPV 0.000037–0.000778 0–0.1
-  HR-other HPV 0.000184–0.003888 0–0.1
-  HR-16 HPV 0.000184–0.003888 0.1–1
-  HR-18 HPV 0.000184–0.003888 0–0.1
CIN  1 to CIN 2,3
- LR HPV 0.000037–0.000778 0.1–6
-  HR-other HPV 0.000184–0.003888 0.1–6
- HR-16 HPV 0.000184–0.003888 0.1–6
-  HR-18 HPV 0.000184–0.003888 0.1–6
CIN 2,3 to local cancere
- HR-other HPV 0.000015–0.006000 0.5–4
-  HR-16 HPV 0.000015–0.006000 0.5–6
-  HR-18 HPV 0.000015–0.006000 0.5–6
Local to regional invasive cancer 0.020000 –
Regional to distant invasive cancer 0.025000 –
Regression
HPV DNA to normalf
- LR HPV 0.030500 3–8
-  HR-other HPV 0.030500 3–8
-  HR-16 HPV 0.030500 3–8
-  HR-18 HPV 0.030500 3–8
CIN 1 to normalg
- LR HPV 0.030500 0.5–6
-  HR-other HPV 0.030500 0.5–6
-  HR-16 HPV 0.030500 0.5–6
-  HR-18 HPV 0.030500 0.5–6
CIN 2,3 to normalh
- LR HPV 0.001410–0.006497 0.5–6
-  HR-other HPV 0.001410–0.006497 0.5–6
-  HR-16 HPV 0.001410–0.006497 0.5–6
-  HR-18 HPV 0.001410–0.006497 0.5–6
Other
Immunity (HR HPV types only)
- HR-other HPV 0 0.0–0.5
-  HR-16 HPV 0 0.6–1
-  HR-18 HPV 0 0.6–1
Source: Goldie and others 2007 [24].
a HPV, human papillomavirus; DNA, deoxyribonucleic acid; CIN, cervical intraepithelial neoplasia.
b Base case values are monthly probabilities, unless otherwise noted. A hyphenated range reported for a base case value represents age-speciﬁc probabilities. Except where
noted,  the ranges represent multiplier values, which are applied to baseline probabilities during calibration.
c Although baseline rates of progression and the range of multipliers were the same among all HR HPV types, the multipliers were allowed to vary independently by type
in  the parameter searches.
d A proportion of women with HPV who progress to CIN 1 transition directly to CIN 2,3.
e Infection with high risk HPV is considered a necessary condition for progression to invasive cancer.
f We assumed that regression from HPV DNA to normal was  equal among types, and therefore the multipliers were held constant among types in the parameter searches.
g Although baseline rates of regression and the range of multipliers were the same among all HPV types, the multipliers were allowed to vary independently by type in
the  parameter searches.
h 70% of women with CIN 2,3 regress to normal, 15% to HPV, 15% to CIN 1.
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Table  A2
Cost parameters for screening, diagnosis, and treatment, and wage rates by income quintile (2009 US$).
Cost parameter Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Direct
medical
cost per
woman
Woman’s
time and
OOP costs
Direct
medical
cost per
woman
Woman’s
time and
OOP costs
Direct
medical
cost per
woman
Woman’s
time and
OOP costs
Direct
medical
cost per
woman
Woman’s
time and
OOP costs
Direct
medical
cost per
woman
Woman’s
time and
OOP  costs
Screening
Cytology 7.01 2.87 7.01 2.87 7.32 2.87 7.49 2.87 7.96 2.87
VIA  2.24 2.15 2.24 2.15 2.24 2.15 2.24 2.15 2.24 2.15
HPV  rapid test 7.33 2.15 7.33 2.15 7.50 2.15 7.59 2.15 7.92 2.15
Diagnosis
Colposcopy 4.41 2.27 4.41 2.27 4.58 2.27 4.67 2.27 4.93 2.27
Biopsy  5.91 5.91 5.96 5.99 6.06
Treatment
LEEP  66.41 166.00 66.41 166.00 68.01 166.00 68.92 166.00 71.43 166.00
Cryotherapy 10.32 2.27 10.32 2.27
Cold conization 293.15 178.50 293.15 178.50 293.15 178.50 367.54 253.50 367.54 253.50
Simple hysterectomy 409.48 291.00 409.48 291.00 410.60 291.00 446.63 292.00 446.63 292.00
Simple radiotherapy 290.18 252.00 290.18 252.00 292.19 252.00 384.98 252.00 384.98 252.00
Urban  share of
population (percent)
34 (5) 34 (5) 42 (8) 47 (9) 64 (10)
Daily  wage rate 3.00 6.00 10.00 15.00 31.00
Sources: Levin and others (2010) [10]; Shi and others (2012) [27].
Note:  Rural costs are taken from Shi and others (2012). Costs for urban settings and Beijing are taken from Levin and others (2010). Costs represent a weighted average for
urban  and rural for each income quintile.
Numbers in parenthesis indicate the percent of women in each quintile assumed to live in or receive care in Beijing.
OOP  = out of pocket; LEEP = loop electrosurgical excision procedure; VIA = visual inspection with acetic acid.
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Table A3
Cost parameters for out-of-pocket expenses for direct medical, direct non-medical, and total patient costs by income quintile (2009 US$).
Cost parameter Quintile 1 Total Quintile 2 Total Quintile 3 Total Quintile 4 Total Quintile 5 Total
Direct
medical
Direct
non-medical
Direct
medical
Direct
non-medical
Direct
medical
Direct
non-medical
Direct
medical
Direct
non-medical
Direct
medical
Direct
non-medical
Screening
Cytology 1.16 1.16 7.01 3.6 10.64 7.32 5.69 13.01 7.49 8.62 16.11 7.96 17.51 25.47
VIA  2.24 1.11 3.35 2.24 2.4 4.66 2.24 3.80 6.04 2.24 5.75 7.99 2.24 11.68 13.92
HPV  rapid test 7.33 1.24 7.33 7.33 2.3 9.64 7.50 3.63 11.12 7.59 5.50 13.09 7.92 11.16 19.08
Diagnosis
Colposcopy 4.41 0.00 4.41 4.41 2.6 7.00 4.58 4.07 8.65 4.67 6.16 10.83 4.93 12.51 17.44
Biopsy  5.91 110.77 5.91 5.91 5.91 5.96 5.96 5.99 5.99 6.06 6.06
Treatment
LEEP  66.41 110.77 177.17 66.41 194.1 260.52 68.01 285.68 353.69 68.92 415.22 484.13 71.43 808.10 879.53
Cryotherapy 10.32 10.32 10.32 194.1 204.44 0.00 0.00 0.00
Cold  conization 293.15 188.17 481.32 293.15 293.15 293.15 382.67 675.81 367.54 811.69 1179.22 367.54 1512.60 1880.13
Simple
hysterectomy
409.48 309.35 718.83 409.48 280.8 690.32 410.60 689.95 1100.55 446.63 1007.12 1453.75 446.63 1906.04 2352.67
Simple
radiotherapy
290.18  269.68 559.86 290.18 490.7 780.89 292.19 633.49 925.68 384.98 902.93 1287.91 384.98 1720.13 2105.11
Sources:  Levin and others (2010) [10]; Shi and others (2012) [27].
Note:  LEEP = loop electrosurgical excision procedure; OOP = out of pocket; VIA = visual inspection with acetic acid.
The  OOP direct medical costs are 35 percent of total treatment costs shown in annex 16.A1 we assume 35 percent of total treatment costs are privately ﬁnanced in China (WHO Global Health Observatory). The OOP  direct
non-medical costs are transport and waiting times for patients. We  adjusted transport and waiting times obtained from Shy and others (2012) with new estimates of average wage rates by quintile.
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Table  A4
Sensitivity analysis parameter estimates and ranges.
Parameter Point estimate Estimate or range Sources
Screening with cytology: frequency1 and coverage (percent)
Income quintile (lowest to highest)
1.  Once per lifetime 21 21–70 a, b
2.  Once per lifetime 34 34–70 a, b
3.  Three times per lifetime 43 43–70 a, b
4.  Three times per lifetime 47 47–70 a, b
5.  Five times per lifetime 51 51–70 a, b
Loss  to follow up (percent)
Income quintile (lowest to highest)
1  62 15, 39 Assumed
2  40 15, 24 Assumed
3  22 15, 22 Assumed
4  13 15, 17 Assumed
5  5 11, 15 Assumed
Vaccine characteristics
Vaccine cost per fully immunized girl, including wastage and handling (US$) 46 10–100 Assumed
Sources:
a. Gakidou, Nordhagen, and Obermeyer (2008) [37].
b. World Health Organization (2012) [48].
Note:
1.  We estimated the frequency of screening at 1× and 5× per lifetime for all income quintiles in sensitivity analysis.
2.  HPV = human papillomavirus.
Table A5
Sensitivity analysis, for HPV vaccination costs at US$10, US$46 and US$100 per fully vaccinated girl (US$ 2009).
Quintile I II III IV V
HPV vaccination at US$10 per fully vaccinated girl
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $6,217,285 $6,220,191 $6,240,420 $6,246,679 $6,159,970
Gov’t cost/death averted $2161 $2179 $2340 $2399 $2608
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $1,633,160 $2,240,688 $2,785,626 $4,417,303 $7,041,335
Savings as a percentage of income 59% 39% 33% 35% 30%
Cancer reduction 44% 44% 43% 43% 44%
HPV  vaccination at US$46 per fully vaccinated girl
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $31,417,285 $31,420,191 $31,440,420 $31,446,679 $31,359,970
Gov’t cost/death averted $10,920 $11,009 $11,789 $12,076 $13,277
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $1,633,160 $2,240,688 $2,785,626 $4,417,303 $7,041,335
Savings as a percentage of income 59% 39% 33% 35% 30%
Cancer reduction 44% 44% 43% 43% 44%
HPV  vaccination at US$100 per fully vaccinated girl
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $69,217,285 $69,220,191 $69,240,420 $69,246,679 $69,159,970
Gov’t cost/death averted $24,059 $24,254 $25,962 $26,592 $29,280
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $1,633,160 $2,240,688 $2,785,626 $4,417,303 $7,041,335
Savings as a percentage of income 59% 39% 33% 35% 30%
Cancer reduction 44% 44% 43% 43% 44%
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Table A6
Sensitivity analysis, assuming treatment costs increase by 50% and 100% compared to baseline (US$ 2009).
Quintile I II III IV V
Baseline strategy
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $31,417,285 $31,420,191 $31,440,420 $31,446,679 $31,359,970
Gov’t  cost/death averted $10,920 $11,009 $11,789 $12,076 $13,277
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $1,633,160 $2,240,688 $2,785,626 $4,417,303 $7,041,335
Savings as a percentage of income 59% 39% 33% 35% 30%
Cancer reduction 44% 44% 43% 43% 44%
Treatment costs increased by 50%
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $31,035,156 $31,057,311 $31,085,113 $31,103,101 $30,939,508
Gov’t  cost/death averted $10,787 $10,882 $11,655 $11,944 $13,099
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $1,899,093 $2,506,089 $3,040,532 $4,714,290 $7,310,555
Savings as a percentage of income 69% 44% 36% 37% 31%
Cancer reduction 44% 44% 43% 43% 44%
Treatment costs increased by 100%
Deaths averted 2877 2854 2667 2604 2362
Government costs (incremental) $30,647,484 $30,682,085 $30,728,534 $30,760,469 $30,550,290
Gov’t  cost/death averted $10,653 $10,751 $11,522 $11,813 $12,934
Treatment-seeking cases of cancer averted 3540 3511 3312 3256 2999
Patient cost savings $2,165,026 $2,771,490 $3,295,438 $5,011,276 $7,579,775
Savings as a percentage of income 78% 48% 39% 40% 32%
Cancer reduction 44% 44% 43% 43% 44%
Mean  cancer reductions and incremental cost-effectiveness ratios by cost per vaccinated girl and availability of screening test.a
Mean cancer reduction (%) Cost per vaccinated girlb
I$10 I$25 I$50 I$100 I$150 I$200
Quintile 1
Natural history (no screening or vaccination) – – – – – – –
Cytology once per lifetime 0.12 Dom Dom Dom Dom Dom Dom
Vaccination alone 43.94 $513 $1357 $2764 $5578 $8391 $11,205
Vaccination and cytology once per lifetime 44.02 $37,993 $37,993 $37,993 $37,993 $37,993 $37,993
Quintile 2
Natural history (no screening or vaccination) – – – – – – –
Cytology once per lifetime 0.56 Dom Dom Dom $4883 $4883 $4883
Vaccination alone 43.94 $513 $1357 $2764 $5600 $8505 $11,409
Vaccination and cytology once per lifetime 44.11 $17,289 $17,289 $17,289 $17,289 $17,289 $17,289
Quintile 3
Natural history (no screening or vaccination) – – – – – – –
Cytology 3 times per lifetime 4.95 Dom Dom Dom $2766 $2766 $2766
Vaccination alone 43.94 $513 $1357 $2764 $6250 Dom Dom
Vaccination and cytology 3 times per lifetime 46.21 $6314 $6314 $6314 $6314 $9412 $12,568
Quintile 4
Natural history (no screening or vaccination) – – – – – – –
Cytology 3 times per lifetime 6.51 Dom Dom $2575 $2575 $2575 $2575
Vaccination alone 43.94 $513 $1357 $2764 Dom Dom Dom
Vaccination and cytology 3 times per lifetime 47.00 $5612 $5612 $5612 $6426 $9672 $12,919
Quintile 5
Natural history (no screening or vaccination) – – – – – – –
Cytology 5 times per lifetime 14.63 Dom Dom $2323 $2323 $2323 $2323
Vaccination alone 43.94 $513 $1357 $2764 Dom Dom Dom
Vaccination and cytology 5 times per lifetime 51.90 $4511 $4511 $4511 $7098 $10,684 $14,270
Costs are expressed in 2009 US dollars.
a Values represent incremental cost-effectiveness ratios (the ratio of the mean-costs divided by the mean-effects of best-ﬁtting parameter set) expressed as cost per year
of  life saved (international dollars per YLS). “Dom” denotes strategies that were either more costly and less effective or less costly and less effective than alternative options,
and  are thus considered Dom.
b Costs per vaccinated girl includes 3 doses of vaccine, wastage, freight and supplies, administration, immunization support, and programmatic costs.
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